Singular Genomics Systems Inc

OMIC | $0.3975 -2.63% 24K

(0.0% 1d) (-23.6% 1m) (-61.9% 1y) (0.0% 2d) (0.0% 3d) (6.1% 7d) (-11.2% volume)
Earnings Calendar: 2024-03-18
Market Cap: $ 29,386,601
https://singulargenomics.com
Sec Filling | Patents | 138 employees

Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. The Singular Sequencing Engine is the foundational platform technology that forms the basis of Singular Genomics’ products in development and Singular Genomics’ core product tenets: accuracy, speed, flexibility and scale. Singular Genomics’ first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the G4 Integrated Solution. A second integrated solution in development comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution.

t-cell

add to watch list Paper trade email alert is off

Day One Biopharmaceuticals Inc

DAWN 4 | $15.76 6.13% 5.77% 1.9M

Professional, Scientific, and T...

(0.0% 1d) (-0.4% 1m) (12.4% 1y) (0.0% 2d) (0.0% 3d) (5.5% 7d) (22.59% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 1,377,064,089
https://dayonebio.com
Sec Filling | Patents | 20 employees

(US) Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Its name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. The company aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco.

treatment diagnostics cancer

add to watch list Paper trade email alert is off